431 related articles for article (PubMed ID: 36461127)
21. Surveillance of cfDNA Hot Spot Mutations in NSCLC Patients during Disease Progression.
Sestokaite A; Gedvilaite V; Cicenas S; Sabaliauskaite R; Jarmalaite S
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108122
[TBL] [Abstract][Full Text] [Related]
22. Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
Tu HY; Li YS; Bai XY; Sun YL; Zheng MY; Ke EE; Liao RQ; Jiang BY; Lin JX; Huang J; Xu BF; Yang JJ; Zhang XC; Zhou Q; Wang BC; Chen HJ; Tong X; Yu R; Wu X; Zhu D; Wu YL
Clin Lung Cancer; 2022 Mar; 23(2):135-142. PubMed ID: 34645582
[TBL] [Abstract][Full Text] [Related]
23. High-throughput and affordable genome-wide methylation profiling of circulating cell-free DNA by methylated DNA sequencing (MeD-seq) of LpnPI digested fragments.
Deger T; Boers RG; de Weerd V; Angus L; van der Put MMJ; Boers JB; Azmani Z; van IJcken WFJ; Grünhagen DJ; van Dessel LF; Lolkema MPJK; Verhoef C; Sleijfer S; Martens JWM; Gribnau J; Wilting SM
Clin Epigenetics; 2021 Oct; 13(1):196. PubMed ID: 34670587
[TBL] [Abstract][Full Text] [Related]
24. Quantitative detection of ALK fusion breakpoints in plasma cell-free DNA from patients with non-small cell lung cancer using PCR-based target sequencing with a tiling primer set and two-step mapping/alignment.
Kunimasa K; Kato K; Imamura F; Kukita Y
PLoS One; 2019; 14(9):e0222233. PubMed ID: 31513617
[TBL] [Abstract][Full Text] [Related]
25. Genetic profiling of circulating cell-free DNA from cerebrospinal fluid and paired plasma in ALK-positive lung cancer with brain metastases.
Shi L; Guo L; Tao H; Meng Q; Tong L; Tang J; Li K; Zhang S; Liu Z
Thorac Cancer; 2023 Jul; 14(19):1883-1893. PubMed ID: 37287428
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive DNA methylation analysis of tissue of origin of plasma cell-free DNA by methylated CpG tandem amplification and sequencing (MCTA-Seq).
Liu X; Ren J; Luo N; Guo H; Zheng Y; Li J; Tang F; Wen L; Peng J
Clin Epigenetics; 2019 Jun; 11(1):93. PubMed ID: 31234922
[TBL] [Abstract][Full Text] [Related]
27. HOXA9 gene promotor methylation and copy number variation of SOX2 and HV2 genes in cell free DNA: A potential diagnostic panel for non-small cell lung cancer.
Abou-Zeid A; Hashad D; Baess A; Mosaad M; Tayae E
BMC Cancer; 2023 Apr; 23(1):329. PubMed ID: 37038139
[TBL] [Abstract][Full Text] [Related]
28. ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations.
Peretti U; Ferrara R; Pilotto S; Kinspergher S; Caccese M; Santo A; Brunelli M; Caliò A; Carbognin L; Sperduti I; Garassino M; Chilosi M; Scarpa A; Tortora G; Bria E
Respir Res; 2016 Aug; 17(1):105. PubMed ID: 27561692
[TBL] [Abstract][Full Text] [Related]
29. Genome-Wide Plasma Cell-Free DNA Methylation Profiling Identifies Potential Biomarkers for Lung Cancer.
Xu W; Lu J; Zhao Q; Wu J; Sun J; Han B; Zhao X; Kang Y
Dis Markers; 2019; 2019():4108474. PubMed ID: 30867848
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
[TBL] [Abstract][Full Text] [Related]
31. Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification.
Liu L; Toung JM; Jassowicz AF; Vijayaraghavan R; Kang H; Zhang R; Kruglyak KM; Huang HJ; Hinoue T; Shen H; Salathia NS; Hong DS; Naing A; Subbiah V; Piha-Paul SA; Bibikova M; Granger G; Barnes B; Shen R; Gutekunst K; Fu S; Tsimberidou AM; Lu C; Eng C; Moulder SL; Kopetz ES; Amaria RN; Meric-Bernstam F; Laird PW; Fan JB; Janku F
Ann Oncol; 2018 Jun; 29(6):1445-1453. PubMed ID: 29635542
[TBL] [Abstract][Full Text] [Related]
32. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.
Camidge DR; Skokan M; Kiatsimkul P; Helfrich B; Lu X; Barón AE; Schulte N; Maxson D; Aisner DL; Franklin WA; Doebele RC; Varella-Garcia M
Cancer; 2013 Nov; 119(22):3968-75. PubMed ID: 24022839
[TBL] [Abstract][Full Text] [Related]
33. Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in
Dietz S; Christopoulos P; Gu L; Volckmar AL; Endris V; Yuan Z; Ogrodnik SJ; Zemojtel T; Heussel CP; Schneider MA; Meister M; Muley T; Reck M; Schlesner M; Thomas M; Stenzinger A; Sültmann H
Cold Spring Harb Mol Case Stud; 2019 Dec; 5(6):. PubMed ID: 31753813
[TBL] [Abstract][Full Text] [Related]
34. Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea.
Ahn BC; Lee S; Lee J; Lee JB; Hong MH; Lim SM; Jain S; Olsen S; Cho BC
Cancer Treat Res Commun; 2023; 36():100715. PubMed ID: 37307681
[TBL] [Abstract][Full Text] [Related]
35. Genome-wide combination profiling of DNA copy number and methylation for deciphering biomarkers in non-small cell lung cancer patients.
Son JW; Jeong KJ; Jean WS; Park SY; Jheon S; Cho HM; Park CG; Lee HY; Kang J
Cancer Lett; 2011 Dec; 311(1):29-37. PubMed ID: 21757291
[TBL] [Abstract][Full Text] [Related]
36. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
37. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer.
Barault L; Amatu A; Siravegna G; Ponzetti A; Moran S; Cassingena A; Mussolin B; Falcomatà C; Binder AM; Cristiano C; Oddo D; Guarrera S; Cancelliere C; Bustreo S; Bencardino K; Maden S; Vanzati A; Zavattari P; Matullo G; Truini M; Grady WM; Racca P; Michels KB; Siena S; Esteller M; Bardelli A; Sartore-Bianchi A; Di Nicolantonio F
Gut; 2018 Nov; 67(11):1995-2005. PubMed ID: 28982739
[TBL] [Abstract][Full Text] [Related]
38. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
39. ALK-Rearranged Non-Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism.
Zer A; Moskovitz M; Hwang DM; Hershko-Klement A; Fridel L; Korpanty GJ; Dudnik E; Peled N; Shochat T; Leighl NB; Liu G; Feld R; Burkes R; Wollner M; Tsao MS; Shepherd FA
Clin Lung Cancer; 2017 Mar; 18(2):156-161. PubMed ID: 27913214
[TBL] [Abstract][Full Text] [Related]
40. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
